Systagenix Product Launch



For Immediate Release

26 October 2009

Advanced Medical Solutions Group plc

(“AMS” or the “Group”)

Launch of new silver alginate dressing

Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the global medical technology company, today announces 

that Systagenix Wound Management (“Systagenix”), the exclusive  marketing and distribution partner for the Group‘s fibre-based silver alginate technology, has expanded its SILVERCEL* anti-microbial wound dressings offering with the introduction of SILVERCEL* Non-Adherent Hydro-Alginate Dressing.  The new product has recently been launched in the US with introduction into Europe and other international markets during October.

Silver is widely recognised as a safe and effective broad-spectrum anti-microbial agent for infection control. In 2003, 

AMS developed a range of wound dressings whereby silver fibres were incorporated into its proprietry calcium alginate technology which allows a controlled and sustained release of silver into the wound without compromising the performance of the base alginate – a natural wound dressing derived from seaweed.  Following regulatory approvals, these products were launched under the SILVERCEL* brand and are sold by Systagenix in all the key advanced woundcare markets worldwide. The global silver alginate market is currently estimated at around $350 million and growing at 15% per annum.

The new product announced today, SILVERCEL* Non-Adherent, is a dressing with the unique benefit of a perforated film on both sides of the existing SILVERCEL* dressing. Suitable for use on moderately to heavily exuding infected wounds and effective against a broad range of micro-organisms, it is specifically designed for easy removal thus minimising the trauma associated with dressing changes.

UK based Systagenix has clear objectives to build on 75 years of history at the forefront of pioneering and innovative woundcare to become the world’s strongest and most admired woundcare company. It currently supplies over 30 million wound dressings a month to treat patients in hospitals, nursing homes and in their own homes in over 100 countries.

Commenting on this announcement, Dr. Don Evans, Chief Executive Officer of Advanced Medical Solutions, said:

“With their strong global presence and commitment to inventive products for chronic and acute wound management, Systagenix is an ideal partner for the marketing and distribution of our fibre-based silver alginate technology. The introduction of this latest product innovation is another key milestone for AMS in exploiting the dynamic silver alginate market and launching novel woundcare products with major global players.”

For further information, please contact:

Advanced Medical Solutions Group plc
Don Evans, Chief Executive Officer Mary Tavener, Finance Director www.admedsol.com	Tel: +44 (0) 1606 545508
Buchanan Communications
Mark Court / Stasa Filiplic	Tel: +44 (0) 20 7466 5000
Investec Bank plc	Tel: +44 (0) 20 7597 5970
Tim Pratelli / Daniel Adams

Notes to Editors:

Advanced Medical Solutions develops and manufactures products for the $15 billion global woundcare market.

Founded in 1991 and quoted on AIM, Advanced Medical Solutions is focused on the design, development and manufacture of innovative products for advanced woundcare and wound closure.  

The advanced woundcare products are based on the moist wound healing principle. AMS uses its in–house technology to provide a vertically integrated ‘one stop shop’ for all categories of moist wound healing products. The Company has the capability to move a product from design and development through to production and delivery for distribution and sale into customer markets.

AMS’ technology in cyanoacrylate based tissue adhesives is used for the closure of small cuts and trauma wounds through to large surgical incisions, and also for protecting or sealing skin to prevent breakdown or infection. 

AMS’ products which currently serve the majority of the key global markets are sold either direct or through strategic partners and distributors. 

Systagenix Wound Management

Systagenix Wound Management was formed in December 2008 following the management buyout of Johnson & Johnson’s professional wound care business, which had a 75-year heritage.

Systagenix, with its head office based in Gatwick, UK, employs more than 800 people globally. It develops, manufactures and distributes a wide range of unique and advanced wound care products to more than 100 countries worldwide.

With products designed to heal some of the most challenging acute and chronic wounds, Systagenix offers products within various wound care categories, including moist wound healing, anti–microbial and active healing.

END

MSCQXLFLKBBBFBF